Fizazi K - Search Results

1

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Fizazi K, et al. Clin Cancer Res. 2003 Jul;9(7):2587-97. Clin Cancer Res. 2003. PMID: 12855635

2

Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.

Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Yang J, et al. Among authors: fizazi k. Cancer Res. 2001 Jul 15;61(14):5652-9. Cancer Res. 2001. PMID: 11454720

3

A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.

Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ. Fizazi K, et al. Ann Oncol. 2002 Jan;13(1):125-34. doi: 10.1093/annonc/mdf005. Ann Oncol. 2002. PMID: 11863094 Free article. Clinical Trial.

4

Germ-cell tumor survivors: the price for cure.

Fizazi K, Chen I, Logothetis CJ. Fizazi K, et al. Ann Oncol. 2002 Feb;13(2):187-9. doi: 10.1093/annonc/mdf126. Ann Oncol. 2002. PMID: 11885993 Free article. No abstract available.

5

The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.

Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordoñez NG, Troncoso P, Navone NM. Fizazi K, et al. Clin Cancer Res. 2002 Mar;8(3):775-81. Clin Cancer Res. 2002. PMID: 11895908

6

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.

Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Fizazi K, et al. Br J Cancer. 2002 May 20;86(10):1555-60. doi: 10.1038/sj.bjc.6600272. Br J Cancer. 2002. PMID: 12085204 Free PMC article. Clinical Trial.

7

Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.

Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ. Fizazi K, et al. J Clin Oncol. 2004 Oct 1;22(19):3868-76. doi: 10.1200/JCO.2004.04.008. Epub 2004 Aug 9. J Clin Oncol. 2004. PMID: 15302906

8

High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.

Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. Fizazi K, et al. Anticancer Res. 2004 Sep-Oct;24(5A):2897-903. Anticancer Res. 2004. PMID: 15517894 Free article.

9

[Preclinical models of prostate cancer].

Fizazi K, Navone NM. Fizazi K, et al. Bull Cancer. 2005 Feb;92(2):129-41. Bull Cancer. 2005. PMID: 15749642 Free article. Review. French.

10

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.

Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S; Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Fizazi K, et al. Lancet Oncol. 2007 Nov;8(11):994-1000. doi: 10.1016/S1470-2045(07)70284-X. Epub 2007 Oct 17. Lancet Oncol. 2007. PMID: 17942366

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

521 results

Search Page